Yield10 Bioscience Current Financial Leverage
| YTEN Stock | USD 0.26 0.01 3.70% |
Yield10 Bioscience holds a debt-to-equity ratio of 0.284. At this time, Yield10 Bioscience's Net Debt is very stable compared to the past year. As of the 19th of April 2024, Short Term Debt is likely to grow to about 1.7 M, while Short and Long Term Debt Total is likely to drop about 2.9 M. Yield10 Bioscience's financial risk is the risk to Yield10 Bioscience stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Yield10 Bioscience's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Yield10 Bioscience's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Yield10 Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Yield10 Bioscience's stakeholders.
For most companies, including Yield10 Bioscience, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Yield10 Bioscience the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 11.2322 | Book Value (0.21) | Operating Margin (240.28) | Return On Assets (1.50) | Return On Equity (15.08) |
Yield10 |
Yield10 Bioscience Financial Leverage Rating
Yield10 Bioscience bond ratings play a critical role in determining how much Yield10 Bioscience have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Yield10 Bioscience's borrowing costs.| Piotroski F Score | 3 Frail |
| Beneish M Score | -8.31 Unlikely Manipulator |
Yield10 Bioscience Debt to Cash Allocation
As Yield10 Bioscience follows its natural business cycle, the capital allocation decisions will not magically go away. Yield10 Bioscience's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 3.18 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Yield10 Bioscience has a current ratio of 6.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Yield10 Bioscience until it has trouble settling it off, either with new capital or with free cash flow. So, Yield10 Bioscience's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Yield10 Bioscience sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Yield10 to invest in growth at high rates of return. When we think about Yield10 Bioscience's use of debt, we should always consider it together with cash and equity.Yield10 Bioscience Other Assets Over Time
Yield10 Bioscience Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Yield10 Bioscience's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Yield10 Bioscience, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a a Yield10 Bioscience debt ratio should be compared their industry average or other competing firms.Yield10 Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning Yield10 Bioscience Use of Financial Leverage
Yield10 Bioscience financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Yield10 Bioscience's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Yield10 Bioscience assets, the company is considered highly leveraged. Understanding the composition and structure of overall Yield10 Bioscience debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to Yield10 Bioscience's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Yield10 Bioscience's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 3.2 M | 2.9 M | |
| Net Debt | 2.1 M | 2.2 M | |
| Long Term Debt | 0.00 | 0.00 | |
| Short Term Debt | 1.7 M | 1.7 M | |
| Short and Long Term Debt | 885.6 K | 787.2 K | |
| Net Debt To EBITDA | (0.15) | (0.14) | |
| Debt To Equity | (1.28) | (1.22) | |
| Interest Debt Per Share | 0.40 | 0.42 | |
| Debt To Assets | 0.81 | 0.85 | |
| Long Term Debt To Capitalization | (1.59) | (1.67) | |
| Total Debt To Capitalization | 4.57 | 4.80 | |
| Debt Equity Ratio | (1.28) | (1.22) | |
| Debt Ratio | 0.81 | 0.85 | |
| Cash Flow To Debt Ratio | (3.17) | (3.33) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Yield10 Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Yield10 Bioscience's short interest history, or implied volatility extrapolated from Yield10 Bioscience options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Yield10 Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Yield10 Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Yield10 Bioscience Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Yield10 Bioscience Stock:Check out the analysis of Yield10 Bioscience Fundamentals Over Time. To learn how to invest in Yield10 Stock, please use our How to Invest in Yield10 Bioscience guide.Note that the Yield10 Bioscience information on this page should be used as a complementary analysis to other Yield10 Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Yield10 Stock analysis
When running Yield10 Bioscience's price analysis, check to measure Yield10 Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Yield10 Bioscience is operating at the current time. Most of Yield10 Bioscience's value examination focuses on studying past and present price action to predict the probability of Yield10 Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Yield10 Bioscience's price. Additionally, you may evaluate how the addition of Yield10 Bioscience to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Yield10 Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Yield10 Bioscience. If investors know Yield10 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Yield10 Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 0.008 | Quarterly Revenue Growth (1.00) | Return On Assets (1.50) | Return On Equity (15.08) |
The market value of Yield10 Bioscience is measured differently than its book value, which is the value of Yield10 that is recorded on the company's balance sheet. Investors also form their own opinion of Yield10 Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Yield10 Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Yield10 Bioscience's market value can be influenced by many factors that don't directly affect Yield10 Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Yield10 Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Yield10 Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Yield10 Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.